In an interview with Applied Clinical Trials Associate Editor Don Tracy, Graham Clark, CEO, Phastar, discusses key objectives for attending SCOPE, the rise of real-world evidence, and partnerships critical to improving the success of clinical trial outcomes.
ACT: What are Phastar’s key objectives for attending SCOPE 2025, and how do you see the conference shaping discussions on statistical analysis and data-driven trial optimization?
Clark: I think there are a number of reasons that we’re here. We get the opportunity to see our clients, we get the opportunity to see prospects, we get to talk with everybody else in the industry that we partner with, and we get a general view of everything that's going on in our industry to deal with the challenges and opportunities in the clinical trial space. Ultimately, we're here to showcase our clinical intelligence portal and the work that we've done on advanced visualizations and AI-driven analytics to provide real-time data. This includes dealing with some challenges and opportunities the market sees around complex site monitoring and the elapsed time between the first and last patients going through the process.
We’re delighted to have received the Best in Show award for that clinical intelligence portal here at SCOPE. It’s been a great time for us.
ACT: With the rise of real-world evidence and decentralized trials, how does Phastar ensure data consistency and reliability across diverse sources?
Clark: There are two ways we do that. The first thing, the bedrock of everything, is rigorous data management. The second is providing great mechanisms to deliver and visualize. By standardizing and harmonizing the data through our rigorous data management, we provide clean, high-quality data sets that people can work from. Then, when you overlay a visualization or clinical intelligence platform on top of that, you provide real-time data and analytics that help people make fast, informed decisions and give access to a wider array of decision-makers within organizations to speed up the clinical trial process.
ACT: What types of partnerships—whether with sponsors, CROs, or technology providers—are most critical for improving clinical trial outcomes?
Clark: There are hundreds, if not thousands, of people here, and the permutations of partnerships that you could have are almost endless. For me, everything has to be anchored in solving a problem for the customers. There's no point in having partnerships for the sake of having partnerships. There are always challenges, issues, and opportunities in the market that people working together can solve more readily and easily than people trying to do this on their own.
We recently formed a partnership with Beaconcure to enhance interactivity on tables, figures, and listings between CROs and sponsors. That piece of technology is providing a much better way for sponsors and the CRO community to communicate with each other, allowing the review processes for all of those documents to be completed much more quickly than before. Start with the problem, start with the customer, and develop partnerships that genuinely address the customer’s needs.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.